NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00699816,Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients,https://clinicaltrials.gov/study/NCT00699816,,COMPLETED,"To prove that the efficacy and safety of 'Green Cross CELL\* Immuncell-LC group' is superior to 'non-treatment group(Control group)' in patient undergone curative resection(PEIT, RFA or operation) for hepatocellular carcinoma in Korea",YES,Hepatocellular Carcinoma,BIOLOGICAL: Immuncell-LC,"Recurrence Free Survival(RFS), RFS was measured from the date of randomization to the first recurrence or to death from any cause., Every 3months from the baseline for 24 months and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit)|Recurrence Free Survival(RFS) Rate, RFS rate was measured from the date of randomization to the first recurrence or to death from any cause., Every 3months from the baseline for 24 months, and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit)","Overall Survival(OS), Overall survival was measured from the date of randomization until death from any cause., Every 3months from the baseline for 24 months, and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit)|Cancer-specific Survivals, Cancer-specific survival was measured from the date of randomization until death resulting from HCC., Every 3 months from baseline for 24 months, and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit)|Overall Survival(OS) Rate, Overall survival rate was measured from the date of randomization until death from any cause., Every 3months from the baseline for 24 months, and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit)|Cancer-specific Survival Rate, Cancer-specific survival rate was measured from the date of randomization until death resulting from HCC., Every 3 months from baseline for 24 months, and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit)",,GC Cell Corporation,,ALL,"ADULT, OLDER_ADULT",PHASE3,230,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,IIC-I01,2008-07,2012-11,2012-11,2008-06-18,2015-09-24,2023-07-11,"Korea University Ansan Hospital, Ansan si, Gojan1-dong/Danwon-gu, 425-707, Korea, Republic of|Korea University Guro Hospital, Seoul, Guro 2-Dong, Guro-Gu, 152-703, Korea, Republic of|Samsung Medical Center, Seoul, Ilwon-dong/Gangnam-gu, 135-710, Korea, Republic of|Seoul Asan Medical center, Seoul, Pungnab2-dong/Songpa-gu, 138-736, Korea, Republic of|Seoul National University Hospital, Seoul, Yeongun-dong/Jongro-gu, 110-744, Korea, Republic of",
